SMT201600055B - Composizione farmaceutica per il trattamento o la prevenzione del glaucoma - Google Patents
Composizione farmaceutica per il trattamento o la prevenzione del glaucomaInfo
- Publication number
- SMT201600055B SMT201600055B SM201600055T SM201600055T SMT201600055B SM T201600055 B SMT201600055 B SM T201600055B SM 201600055 T SM201600055 T SM 201600055T SM 201600055 T SM201600055 T SM 201600055T SM T201600055 B SMT201600055 B SM T201600055B
- Authority
- SM
- San Marino
- Prior art keywords
- glaucoma
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009082725 | 2009-03-30 | ||
| PCT/JP2010/055719 WO2010113957A1 (ja) | 2009-03-30 | 2010-03-30 | 緑内障の治療又は予防のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600055B true SMT201600055B (it) | 2016-04-29 |
Family
ID=42828246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600055T SMT201600055B (it) | 2009-03-30 | 2016-02-24 | Composizione farmaceutica per il trattamento o la prevenzione del glaucoma |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8685986B2 (it) |
| EP (1) | EP2415763B1 (it) |
| JP (2) | JP5300033B2 (it) |
| KR (1) | KR101681347B1 (it) |
| CN (1) | CN102448940B (it) |
| AU (1) | AU2010231630B2 (it) |
| CA (1) | CA2757291C (it) |
| CY (1) | CY1117193T1 (it) |
| DK (1) | DK2415763T3 (it) |
| ES (1) | ES2564010T3 (it) |
| HK (1) | HK1170490A1 (it) |
| HR (1) | HRP20160104T1 (it) |
| HU (1) | HUE026742T2 (it) |
| PL (1) | PL2415763T3 (it) |
| PT (1) | PT2415763E (it) |
| SI (1) | SI2415763T1 (it) |
| SM (1) | SMT201600055B (it) |
| WO (1) | WO2010113957A1 (it) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2264009T (pt) | 2008-03-12 | 2019-04-29 | Ube Industries | Composto do ácido piridilaminoacético |
| PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
| JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
| CA2773998A1 (en) * | 2009-09-11 | 2011-03-17 | Ube Industries, Ltd. | Substituted carbonyl compound |
| AU2010336248A1 (en) | 2009-12-25 | 2012-08-02 | Ube Industries, Ltd. | Aminopyridine compound |
| WO2014010654A2 (ja) * | 2012-07-13 | 2014-01-16 | 参天製薬株式会社 | スルホンアミド化合物の組み合わせ |
| US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| TW201527282A (zh) | 2013-03-28 | 2015-07-16 | Ube Industries | 取代聯芳基化合物 |
| WO2015105134A1 (ja) | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 |
| CA2936026C (en) | 2014-01-10 | 2022-04-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
| EP3093019B1 (en) * | 2014-01-10 | 2021-05-26 | Santen Pharmaceutical Co., Ltd | Pharmaceutical composition containing pyridylamino acetic acid compound |
| JP6572890B2 (ja) * | 2014-06-10 | 2019-09-11 | 宇部興産株式会社 | ヘテロ芳香族スルホンアミド化合物の製造方法 |
| US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
| WO2015190507A1 (ja) * | 2014-06-10 | 2015-12-17 | 宇部興産株式会社 | Ｎ－置換スルホンアミド化合物およびその製造方法 |
| JP2017206445A (ja) * | 2014-09-26 | 2017-11-24 | 宇部興産株式会社 | 呼吸器疾患の治療及び／又は予防のための医薬組成物 |
| TWI755356B (zh) * | 2015-07-01 | 2022-02-21 | 日商參天製藥股份有限公司 | 含檸檬酸酯之緩釋劑之用途 |
| US20180200239A1 (en) * | 2015-07-09 | 2018-07-19 | Santen Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound |
| JP7250685B2 (ja) | 2017-09-29 | 2023-04-03 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬 |
| CA3086457A1 (en) | 2017-12-21 | 2019-06-27 | Santen Pharmaceutical Co., Ltd. | Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor |
| CN111491636A (zh) | 2017-12-21 | 2020-08-04 | 参天制药株式会社 | 奥米帕格的组合 |
| US11666563B2 (en) * | 2017-12-28 | 2023-06-06 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
| KR20220089106A (ko) | 2020-12-21 | 2022-06-28 | 이성규 | 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| CA2319198C (en) | 1998-01-27 | 2011-02-22 | Aventis Pharmaceuticals Products Inc. | Substituted oxoazaheterocyclyl factor xa inhibitors |
| WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| AU2001297521B2 (en) | 2001-10-26 | 2007-10-04 | Allergan, Inc. | Co-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| JP2005521668A (ja) | 2002-01-31 | 2005-07-21 | ファイザー・プロダクツ・インク | （３−｛［４−ｔｅｒｔ−ブチル−ベンジル）−（ピリジン−３−スルホニル）−アミノ］−メチル｝−フェノキシ）−酢酸の代謝物 |
| RU2306309C2 (ru) | 2002-03-05 | 2007-09-20 | Оно Фармасьютикал Ко., Лтд. | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний |
| US20070000939A1 (en) | 2002-10-29 | 2007-01-04 | Vasilios Vasiadis | Device for handling and orientating pills or tablets in a precise manner |
| JP2006519250A (ja) | 2003-03-04 | 2006-08-24 | ファイザー・プロダクツ・インク | 医療処置におけるｅｐ２選択的受容体アゴニストの使用 |
| GB0329620D0 (en) | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
| WO2005072743A1 (ja) | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
| JP2007186424A (ja) | 2004-11-26 | 2007-07-26 | Ono Pharmaceut Co Ltd | 気管支拡張剤 |
| EP1714961B1 (en) | 2004-02-12 | 2015-12-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| WO2006009876A2 (en) * | 2004-06-17 | 2006-01-26 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| JP4966866B2 (ja) | 2005-01-14 | 2012-07-04 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ５アンタゴニストとしてのチアゾール−４−カルボキサミド誘導体 |
| WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
| AU2006275263A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd | EP4 receptor agonist, compositions and methods thereof |
| EP1951701A2 (en) | 2005-08-09 | 2008-08-06 | Asterand Uk Limited | Ep2 receptor agonists |
| US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
| AU2007280130B2 (en) | 2006-07-28 | 2011-09-22 | Pfizer Products Inc. | EP2 agonists |
| FI123744B (fi) * | 2006-09-06 | 2013-10-15 | Sandvik Mining & Constr Oy | Menetelmä kallion poraamiseksi |
| PT2264009T (pt) | 2008-03-12 | 2019-04-29 | Ube Industries | Composto do ácido piridilaminoacético |
| PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
-
2010
- 2010-03-30 PL PL10758728T patent/PL2415763T3/pl unknown
- 2010-03-30 CA CA2757291A patent/CA2757291C/en active Active
- 2010-03-30 ES ES10758728.9T patent/ES2564010T3/es active Active
- 2010-03-30 DK DK10758728.9T patent/DK2415763T3/en active
- 2010-03-30 KR KR1020117025638A patent/KR101681347B1/ko active IP Right Grant
- 2010-03-30 AU AU2010231630A patent/AU2010231630B2/en active Active
- 2010-03-30 JP JP2011507220A patent/JP5300033B2/ja active Active
- 2010-03-30 WO PCT/JP2010/055719 patent/WO2010113957A1/ja active Application Filing
- 2010-03-30 SI SI201031130A patent/SI2415763T1/sl unknown
- 2010-03-30 HU HUE10758728A patent/HUE026742T2/en unknown
- 2010-03-30 EP EP10758728.9A patent/EP2415763B1/en active Active
- 2010-03-30 PT PT107587289T patent/PT2415763E/pt unknown
- 2010-03-30 CN CN201080023601.4A patent/CN102448940B/zh active Active
- 2010-03-30 US US13/260,946 patent/US8685986B2/en active Active
-
2012
- 2012-11-09 HK HK12111327.7A patent/HK1170490A1/zh unknown
-
2013
- 2013-04-08 JP JP2013080307A patent/JP5556924B2/ja active Active
-
2016
- 2016-01-29 HR HRP20160104T patent/HRP20160104T1/hr unknown
- 2016-02-15 CY CY20161100125T patent/CY1117193T1/el unknown
- 2016-02-24 SM SM201600055T patent/SMT201600055B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2564010T3 (es) | 2016-03-17 |
| HK1170490A1 (zh) | 2013-03-01 |
| HUE026742T2 (en) | 2016-07-28 |
| WO2010113957A1 (ja) | 2010-10-07 |
| JP2013151548A (ja) | 2013-08-08 |
| JP5556924B2 (ja) | 2014-07-23 |
| DK2415763T3 (en) | 2016-03-07 |
| CA2757291C (en) | 2017-05-23 |
| KR101681347B1 (ko) | 2016-11-30 |
| PT2415763E (pt) | 2016-03-30 |
| CA2757291A1 (en) | 2010-10-07 |
| KR20120003475A (ko) | 2012-01-10 |
| JP5300033B2 (ja) | 2013-09-25 |
| PL2415763T3 (pl) | 2016-05-31 |
| CY1117193T1 (el) | 2017-04-05 |
| CN102448940B (zh) | 2015-10-21 |
| US8685986B2 (en) | 2014-04-01 |
| AU2010231630A1 (en) | 2011-11-10 |
| AU2010231630B2 (en) | 2015-02-12 |
| EP2415763B1 (en) | 2016-01-27 |
| US20120190852A1 (en) | 2012-07-26 |
| HRP20160104T1 (hr) | 2016-03-25 |
| EP2415763A1 (en) | 2012-02-08 |
| CN102448940A (zh) | 2012-05-09 |
| EP2415763A4 (en) | 2012-08-15 |
| JPWO2010113957A1 (ja) | 2012-10-11 |
| SI2415763T1 (sl) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600055B (it) | Composizione farmaceutica per il trattamento o la prevenzione del glaucoma | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| HK1217339A1 (zh) | 治療或預防大腸桿菌導致的經口感染的組合物和方法 | |
| HK1172269A1 (en) | Pharmaceutical composition for treatment of dry eye syndrome | |
| IL216800A (en) | Preparation for the treatment of dry eye syndrome | |
| SMT201500189T1 (it) | Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia | |
| IL224215A (en) | An integrated drug for the treatment of functional diseases or conditions of the gastrointestinal system | |
| PT2429507T (pt) | Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| EP2911683A4 (en) | INCREASED COMPOSITION FOR THE TREATMENT OF DISEASES WITH ALLOGENIC AUTOPHAGOSOMES | |
| IT1397838B1 (it) | Composizione per la cura delle piante | |
| SMT201600126B (it) | Solfonammidi per la prevenzione del diabete | |
| HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
| SMT201600268B (it) | Composizione per il trattamento delle neuropatie | |
| IL200753A (en) | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis | |
| EP2271328A4 (en) | ANTISEPTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS | |
| PT2344166E (pt) | Composição farmacêutica para o tratamento da irritação gastrointestinal | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| PL2814462T3 (pl) | Kompozycja farmaceutyczna na bazie oleju do leczenia chorób przewodu pokarmowego | |
| IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| IL215854A0 (en) | Pharmaceutical compositions for the treatment of nasal polyposis | |
| IT1391251B1 (it) | Composizione per il trattamento delle patologie articolari | |
| IT1397219B1 (it) | Composizione farmaceutica o dietetica per il trattamento dell'atopia |